Pyrrolidinones
-
Subject Areas on Research
- A mutation in the glycine binding pocket of the N-methyl-D-aspartate receptor NR1 subunit alters agonist efficacy.
- Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment.
- Arrestin-biased AT1R agonism induces acute catecholamine secretion through TRPC3 coupling.
- Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials.
- Effects of interleukin-1 on calcium signaling and the increase of filamentous actin in isolated and in situ articular chondrocytes.
- Effects of raltegravir on 2-long terminal repeat circle junctions in HIV type 1 viremic and aviremic patients.
- Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients.
- Enhanced bleomycin-induced pulmonary damage in mice lacking extracellular superoxide dismutase.
- Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
- Glucose recovery with bare and hydrogel-coated microdialysis probes: experiment and simulation of temporal effects.
- Inositol pyrophosphates modulate S phase progression after pheromone-induced arrest in Saccharomyces cerevisiae.
- Luteinizing hormone (LH) drives diverse intracellular calcium second messenger signals in isolated porcine ovarian thecal cells: preferential recruitment of intracellular Ca2+ oscillatory cells by higher concentrations of LH.
- Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
- Mechanism of regulation of casein kinase I activity by group I metabotropic glutamate receptors.
- Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo.
- Phosphatidylinositol 4,5-bisphosphate hydrolysis mediates histamine-induced KCNQ/M current inhibition.
- Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).
- Raltegravir-based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virus-infected patients after solid organ transplantation.
- Rapid preparation and characterization of uniform, large, spherical Ag particles through a simple wet-chemical route.
- Receptor-induced transient reduction in plasma membrane PtdIns(4,5)P2 concentration monitored in living cells.
- Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation.